Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Lilly's Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.
The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.